Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RLMD [NASD]
Relmada Therapeutics, Inc.
Healthcare | Drug Manufacturers - Specialty & Generic | USA
statements
Index- P/E- EPS (ttm)-3.78 Insider Own1.60% Shs Outstand16.26M Perf Week-9.78%
Market Cap573.18M Forward P/E- EPS next Y-5.95 Insider Trans-31.52% Shs Float15.84M Perf Month-9.46%
Income-59.50M PEG- EPS next Q-1.39 Inst Own58.50% Short Float5.36% Perf Quarter-7.02%
Sales- P/S- EPS this Y-392.00% Inst Trans1.73% Short Ratio13.21 Perf Half Y4.30%
Book/sh6.49 P/B5.16 EPS next Y-1.50% ROA-48.20% Target Price- Perf Year-18.23%
Cash/sh6.84 P/C4.89 EPS next 5Y- ROE-50.30% 52W Range28.40 - 54.00 Perf YTD4.46%
Dividend- P/FCF- EPS past 5Y-30.00% ROI- 52W High-37.96% Beta0.35
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low17.96% ATR1.69
Employees14 Current Ratio9.40 Sales Q/Q- Oper. Margin- RSI (14)36.07 Volatility5.08% 5.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-186.80% Profit Margin- Rel Volume0.68 Prev Close33.61
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume64.25K Price33.50
Recom1.50 SMA20-8.49% SMA50-6.36% SMA200-5.83% Volume43,491 Change-0.33%
Oct-28-20Downgrade Goldman Buy → Neutral $69 → $40
Jul-14-20Initiated Oppenheimer Outperform $75
May-04-20Initiated SunTrust Buy $75
Apr-21-20Initiated Goldman Buy $63
Jan-27-20Initiated Jefferies Buy $75
Jan-10-20Initiated SVB Leerink Outperform $50
Dec-16-19Initiated Guggenheim Buy $64
May-12-21 04:10PM  
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
PR Newswire
02:30PM  
Relmada Therapeutics, Inc. to Host Earnings Call
ACCESSWIRE
May-06-21 04:30PM  
Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021
PR Newswire
May-01-21 08:30AM  
Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
PR Newswire
Apr-29-21 08:30AM  
Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting
PR Newswire
Apr-28-21 08:30AM  
Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
PR Newswire
Apr-27-21 08:30AM  
Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021
PR Newswire
Apr-01-21 08:00AM  
Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
PR Newswire
Mar-23-21 04:23PM  
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
PR Newswire
02:30PM  
Relmada Therapeutics, Inc. to Host Earnings Call
ACCESSWIRE
Mar-18-21 05:22PM  
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021
PR Newswire
Mar-11-21 08:30AM  
Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference
PR Newswire
Mar-03-21 02:46AM  
What Kind Of Shareholders Hold The Majority In Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shares?
Simply Wall St.
Feb-23-21 08:30AM  
Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference
PR Newswire
Dec-23-20 08:42AM  
Is the Options Market Predicting a Spike in Relmada (RLMD) Stock?
Zacks
Dec-09-20 03:42PM  
Is RLMD A Good Stock To Buy Now?
Insider Monkey
Dec-07-20 08:40AM  
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
PR Newswire
Dec-03-20 02:24AM  
We Think Relmada Therapeutics (NASDAQ:RLMD) Can Afford To Drive Business Growth
Simply Wall St.
Nov-17-20 08:30AM  
Relmada Therapeutics to Participate in Upcoming Investor Conferences
PR Newswire +6.14%
Oct-27-20 08:30AM  
Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
PR Newswire
Oct-23-20 06:52AM  
New Strong Sell Stocks for October 23rd
Zacks
Sep-15-20 01:11PM  
Top Pharmaceutical Stocks for Q4 2020
Investopedia -5.05%
Aug-31-20 10:09AM  
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire
Aug-27-20 02:05PM  
Do Insiders Own Lots Of Shares In Relmada Therapeutics, Inc. (NASDAQ:RLMD)?
Simply Wall St.
Jul-17-20 09:54AM  
Oppenheimer: These 2 Strong Buy Stocks Are Poised to Surge by Over 80%
TipRanks +5.35%
Jul-13-20 08:30AM  
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
PR Newswire
Jul-07-20 07:35AM  
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
Motley Fool
Jun-26-20 07:23AM  
We're Not Worried About Relmada Therapeutics's (NASDAQ:RLMD) Cash Burn
Simply Wall St. -13.23%
Jun-24-20 04:28PM  
Hedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)
Insider Monkey
Jun-23-20 08:30AM  
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
PR Newswire
08:30AM  
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
CNW Group
Jun-09-20 08:34AM  
Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
PR Newswire
May-29-20 08:54AM  
Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
PR Newswire +7.11%
May-27-20 08:00AM  
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
PR Newswire
May-26-20 08:00AM  
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
PR Newswire
May-21-20 12:15PM  
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR Newswire
May-19-20 07:33AM  
Could Opioids Treat Depression? This Biotech Plans to Find Out
Motley Fool
Apr-28-20 08:30AM  
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
PR Newswire +7.70%
Apr-27-20 09:07AM  
Goldman Sachs: 2 Stocks That Could Climb Over 60%
TipRanks
Mar-31-20 08:30AM  
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
PR Newswire +7.40%
Mar-28-20 10:32AM  
Should You Take Comfort From Insider Transactions At Relmada Therapeutics, Inc. (NASDAQ:RLMD)?
Simply Wall St.
Mar-24-20 08:30AM  
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
PR Newswire +10.01%
Mar-09-20 08:30AM  
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
PR Newswire -6.25%
Feb-25-20 09:00AM  
Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
PR Newswire
Feb-06-20 10:00AM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Relmada Therapeutics, Inc.- RLMD
ACCESSWIRE
Jan-10-20 08:07AM  
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
PR Newswire
Jan-02-20 07:35AM  
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE
Dec-20-19 08:00AM  
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
PR Newswire
Dec-10-19 08:00AM  
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
GlobeNewswire
Dec-09-19 04:26PM  
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire
Dec-05-19 07:14AM  
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Benzinga -10.98%
Dec-04-19 07:06AM  
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Benzinga +36.91%
Dec-03-19 11:06PM  
Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
PR Newswire
04:10PM  
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire
Nov-19-19 04:58PM  
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire +5.21%
Nov-13-19 01:46PM  
What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?
Simply Wall St.
Oct-17-19 08:30AM  
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
PR Newswire -17.79%
Oct-15-19 11:26AM  
Relmada Therapeutics stock rockets 137% on positive trial of depression treatment
MarketWatch +134.03%
10:00AM  
Relmada Shares Hit 4-Year High As Depression Drug Aces Midstage Trial
Benzinga
08:00AM  
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
PR Newswire
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CASAMENTO CHARLES JDirectorMay 03Sale38.223,000114,6479,950May 05 05:00 PM
CASAMENTO CHARLES JDirectorApr 01Sale35.433,000106,28112,950Apr 05 04:08 PM
TRAVERSA SERGIOCEOMar 10Sale35.092,983104,67688,774Mar 11 05:51 PM
Shenouda MagedCFOMar 10Sale35.112,37383,3132,228Mar 10 06:18 PM
Kelly Paul EdwardDirectorMar 09Option Exercise3.245,00016,200172,295Mar 11 05:50 PM
TRAVERSA SERGIOCEOMar 09Option Exercise3.2410,00032,40098,774Mar 11 05:51 PM
Kelly Paul EdwardDirectorMar 09Sale35.715,000178,551167,295Mar 11 05:50 PM
TRAVERSA SERGIOCEOMar 09Sale35.657,017250,16991,757Mar 11 05:51 PM
Shenouda MagedCFOMar 09Sale35.567,527267,6934,601Mar 10 06:18 PM
Shenouda MagedCFOMar 08Option Exercise3.2410,00032,40012,228Mar 10 06:18 PM
Shenouda MagedCFOMar 08Sale35.001003,50012,128Mar 10 06:18 PM
CASAMENTO CHARLES JDirectorMar 01Sale33.873,000101,61815,950Mar 02 04:08 PM
Kelly Paul EdwardDirectorFeb 24Option Exercise3.245,00016,200172,295Feb 26 04:49 PM
TRAVERSA SERGIOCEOFeb 24Option Exercise3.2410,00032,40098,774Feb 26 04:50 PM
TRAVERSA SERGIOCEOFeb 24Sale34.2410,000342,39288,774Feb 26 04:50 PM
Kelly Paul EdwardDirectorFeb 24Sale34.195,000170,933167,295Feb 26 04:49 PM
Kelly Paul EdwardDirectorFeb 16Option Exercise6.005,00030,000167,295Feb 17 06:37 PM
TRAVERSA SERGIOCEOFeb 11Option Exercise3.241,4464,68590,220Feb 16 05:10 PM
Shenouda MagedCFOFeb 11Option Exercise3.241,4284,6273,656Feb 16 05:08 PM
Shenouda MagedCFOFeb 11Sale35.391,42850,5422,228Feb 16 05:08 PM
TRAVERSA SERGIOCEOFeb 11Sale35.431,44651,23888,774Feb 16 05:10 PM
TRAVERSA SERGIOCEOFeb 10Sale35.281,93068,09788,774Feb 10 07:25 PM
Shenouda MagedCFOFeb 10Sale35.202,41084,8252,228Feb 10 07:25 PM
TRAVERSA SERGIOCEOFeb 09Sale35.215,963209,93990,704Feb 10 07:25 PM
Shenouda MagedCFOFeb 09Sale35.245,359188,8434,638Feb 10 07:25 PM
Kelly Paul EdwardDirectorFeb 09Sale35.282,06973,005162,295Feb 10 07:25 PM
Kelly Paul EdwardDirectorFeb 08Option Exercise3.243,56911,564165,864Feb 10 07:25 PM
Shenouda MagedCFOFeb 08Option Exercise3.2411,37236,84513,600Feb 10 07:25 PM
TRAVERSA SERGIOCEOFeb 08Option Exercise3.2411,20636,30799,980Feb 10 07:25 PM
Shenouda MagedCFOFeb 08Sale35.043,603126,2429,997Feb 10 07:25 PM
TRAVERSA SERGIOCEOFeb 08Sale35.033,313116,04996,667Feb 10 07:25 PM
Kelly Paul EdwardDirectorFeb 08Sale35.041,50052,560164,364Feb 10 07:25 PM
TRAVERSA SERGIOCEOFeb 03Sale35.001003,50088,874Feb 04 05:40 PM
Shenouda MagedCFOFeb 03Sale35.001003,5002,228Feb 04 05:38 PM
Shenouda MagedCFOFeb 02Option Exercise3.243,20010,3685,428Feb 04 05:38 PM
TRAVERSA SERGIOCEOFeb 02Option Exercise3.2413,28143,03088,774Feb 04 05:42 PM
TRAVERSA SERGIOCEOFeb 02Option Exercise3.243,27810,62192,052Feb 04 05:40 PM
Shenouda MagedCFOFeb 02Sale35.043,100108,6342,328Feb 04 05:38 PM
TRAVERSA SERGIOCEOFeb 02Sale35.083,178111,47088,874Feb 04 05:40 PM
Kelly Paul EdwardDirectorFeb 02Sale35.042,31581,118162,295Feb 03 06:34 PM
Kelly Paul EdwardDirectorFeb 01Option Exercise3.2417,34656,201164,641Feb 03 06:34 PM
CASAMENTO CHARLES JDirectorFeb 01Sale33.633,000100,89818,950Feb 02 05:05 PM
Kelly Paul EdwardDirectorFeb 01Sale35.00311,085164,610Feb 03 06:34 PM
Kelly Paul EdwardDirectorJan 27Option Exercise3.245,00016,200152,295Jan 29 05:20 PM
TRAVERSA SERGIOCEOJan 27Option Exercise3.2410,00032,40085,493Jan 29 05:22 PM
Shenouda MagedCFOJan 27Option Exercise3.243,0009,7205,228Jan 29 05:24 PM
Shenouda MagedCFOJan 27Sale31.933,00095,7782,228Jan 29 05:24 PM
TRAVERSA SERGIOCEOJan 27Sale32.3910,000323,91475,493Jan 29 05:22 PM
Kelly Paul EdwardDirectorJan 27Sale32.465,000162,323147,295Jan 29 05:20 PM
TRAVERSA SERGIOCEOJan 26Sale35.1560021,09075,493Jan 26 07:29 PM
Kelly Paul EdwardDirectorJan 26Sale35.1668524,085147,295Jan 26 07:30 PM
Shenouda MagedCFOJan 26Sale35.1660721,3422,228Jan 26 07:28 PM
TRAVERSA SERGIOCEOJan 25Sale35.291,30045,87776,093Jan 26 07:29 PM
Kelly Paul EdwardDirectorJan 25Sale35.271,30045,851147,980Jan 26 07:30 PM
Shenouda MagedCFOJan 25Sale35.271,28045,1462,835Jan 26 07:28 PM
Shenouda MagedCFOJan 22Option Exercise324.004,0001,296,0006,228Jan 26 07:28 PM
Kelly Paul EdwardDirectorJan 22Option Exercise3.244,08513,235151,380Jan 26 07:30 PM
TRAVERSA SERGIOCEOJan 22Option Exercise3.244,07013,18779,563Jan 26 07:29 PM
Kelly Paul EdwardDirectorJan 22Sale3042.032,1006,388,254149,280Jan 26 07:30 PM
Shenouda MagedCFOJan 22Sale35.552,11375,1244,115Jan 26 07:28 PM
TRAVERSA SERGIOCEOJan 22Sale35.582,17077,21377,393Jan 26 07:29 PM
CASAMENTO CHARLES JDirectorJan 04Sale32.113,00096,34221,950Jan 05 04:00 PM
CASAMENTO CHARLES JDirectorDec 01Sale35.743,000107,21924,950Dec 02 04:01 PM
CASAMENTO CHARLES JDirectorNov 02Sale30.293,00090,86449,173Nov 03 04:03 PM
CASAMENTO CHARLES JDirectorOct 01Sale37.993,000113,95652,173Oct 02 04:02 PM
CASAMENTO CHARLES JDirectorSep 01Sale34.743,000104,20755,173Sep 02 04:36 PM
Kelly Paul EdwardDirectorAug 18Option Exercise3.2422,00071,280149,121Aug 19 04:16 PM
TRAVERSA SERGIOCEOAug 18Option Exercise3.2450,008162,02679,644Aug 19 04:15 PM
CASAMENTO CHARLES JDirectorAug 18Option Exercise3.2426,36285,41360,362Aug 19 04:13 PM
CASAMENTO CHARLES JDirectorAug 03Sale35.743,000107,21334,000Aug 04 03:30 PM
CASAMENTO CHARLES JDirectorJul 01Sale43.893,000131,67737,000Jul 02 01:26 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.